The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+T cells via CD40 ligand
Open accessAbstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system postulated to be a cell-mediated autoimmune disease in which interferon γ (IFN-γ) plays an important role. There is increased IFN-γ secretion in MS, and IFN-γ administration induces exacerbations of disease. We found that interleukin 12 (IL-12) was responsible for raised IFN-γ secretion in MS as anti-IL-12 antibodies reversed raised anti-CD3-induced IFN-γ in MS patients to normal levels. Furthermore, we found a marked increase in T cell receptor-mediated IL-12 secretion in progressive MS patients vs. controls (24.8 ± 7.7 pg/ml vs. 1.5 ± 1.0 pg/ml,P= 0.003) and vs. relapsing–remitting patients (3.7 ± 1.4 pg/ml,P< 0.05). Investigation of the cellular basis for raised IL-12 demonstrated that T cells from MS patients induced IL-12 secretion from non-T cells, and that T cells from MS patients could even drive non-T cells from normal subjects to produce increased IL-12. Anti-CD40 ligand antibody completely blocked IL-12 secretion induced by activated T cells, and we found increased CD40 ligand expression by activated CD4+T cells in MS patients vs. controls. The CD40 ligand-dependent Th1-type immune activation was observed in the progressive but not in the relapsing–remitting form of MS, suggesting a link to disease pathogenesis and progression and providing a basis for immune intervention in the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071
Immunological Aspects of Demyelinating Diseases
Martin, R., McFarland, H. F., & McFarlin, D. E. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.001101 · Cited by 1,010
CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS
SIBLEY, W. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92801-6 · Cited by 594
Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.
Leonard, J. P., Waldburger, K. E., & Goldman, S. J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.381 · Cited by 547
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.
Gerritse, K., Laman, J. D., Noelle, R. J., Aruffo, A., Ledbetter, J. A., Boersma, W. J., & Claassen, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2499 · Cited by 488
Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand
Grewal, I. S., Xu, J., & Flavell, R. A. (1995) · Nature · doi:10.1038/378617a0 · Cited by 464
Windhagen, A., Newcombe, J., Dangond, F., Strand, C., Woodroofe, M. N., Cuzner, M. L., & Hafler, D. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1985 · Cited by 463
Self-citationPrevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40
Durie, F. H., Fava, R. A., Foy, T. M., Aruffo, A., Ledbetter, J. A., & Noelle, R. J. (1993) · Science · doi:10.1126/science.7689748 · Cited by 457
Trembleau, S., Penna, G., Bosi, E., Mortara, A., Gately, M. K., & Adorini, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.817 · Cited by 423
Cited by
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Self-citationBalashov, K. E., Rottman, J. B., Weiner, H. L., & Hancock, W. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6873 · Cited by 849
Self-citationInterleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
T he P athogenesis of O ral L ichen P lanus
Sugerman, P. B., Savage, N. W., Walsh, L. J., Zhao, Z. Z., Zhou, X. J., Khan, A., Seymour, G. J., & Bigby, M. (2002) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130201300405 · Cited by 768
Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses
Kim, J., Ochoa, M.-T., Krutzik, S. R., Takeuchi, O., Uematsu, S., Legaspi, A. J., Brightbill, H. D., Holland, D., Cunliffe, W. J., Akira, S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1535 · Cited by 656
Pizarro, T. T., Michie, M. H., Bentz, M., Woraratanadharm, J., Smith, M. F., Foley, E., Moskaluk, C. A., Bickston, S. J., & Cominelli, F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6829 · Cited by 572
Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
Dominguez-Villar, M., Baecher-Allan, C. M., & Hafler, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2389 · Cited by 526
Self-citationSegal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., & Kasper, L. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70173-x · Cited by 479
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12
Becher, B., Durell, B. G., & Noelle, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15751 · Cited by 386
Neville, L. F., Mathiak, G., & Bagasra, O. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00015-4 · Cited by 350
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12
Becher, B., Durell, B. G., & Noelle, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215751 · Cited by 346
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 344
Self-citationAlterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis
Astier, A. L., Meiffren, G., Freeman, S., & Hafler, D. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29251 · Cited by 292
Self-citationNatarajan, C., & Bright, J. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6506 · Cited by 288
Kim, J. (2005) · Dermatology · doi:10.1159/000087011 · Cited by 282
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
Van Boxel-Dezaire, A. H. H., Hoff, S. C. J., Van Oosten, B. W., Verweij, C. L., Dräger, A. M., Adèr, H. J., Van Houwelingen, J. C., Barkhof, F., Polman, C. H., & Nagelkerken, L. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199906)45:6<695::aid-ana3>3.0.co;2-r · Cited by 265
Neutrophil-related factors as biomarkers in EAE and MS
Rumble, J. M., Huber, A. K., Krishnamoorthy, G., Srinivasan, A., Giles, D. A., Zhang, X., Wang, L., & Segal, B. M. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141015 · Cited by 262
Vaknin-Dembinsky, A., Balashov, K., & Weiner, H. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7768 · Cited by 259
Self-citationCirculating MicroRNAs as biomarkers for disease staging in multiple sclerosis
Gandhi, R., Healy, B., Gholipour, T., Egorova, S., Musallam, A., Hussain, M. S., Nejad, P., Patel, B., Hei, H., Khoury, S., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23880 · Cited by 258
Self-citationInflammation and therapeutic vaccination in CNS diseases
Weiner, H. L., & Selkoe, D. J. (2002) · Nature · doi:10.1038/nature01325 · Cited by 255
Self-citationWeiner, H. L. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1002-8 · Cited by 255
Self-citationMicro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity
Guerau-de-Arellano, M., Smith, K. M., Godlewski, J., Liu, Y., Winger, R., Lawler, S. E., Whitacre, C. C., Racke, M. K., & Lovett-Racke, A. E. (2011) · Brain · doi:10.1093/brain/awr262 · Cited by 188
An emerging role for eotaxins in neurodegenerative disease
Huber, A. K., Giles, D. A., Segal, B. M., & Irani, D. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.010 · Cited by 133
Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis
Tejera-Alhambra, M., Casrouge, A., de Andrés, C., Seyfferth, A., Ramos-Medina, R., Alonso, B., Vega, J., Fernández-Paredes, L., Albert, M. L., & Sánchez-Ramón, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128952 · Cited by 55
Metadata
- Authors
- Balashov, K. E., Smith, D. R., Khoury, S. J., Hafler, D. A., & Weiner, H. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-01-21
- Volume
- 94
- Issue
- 2
- Pages
- 599-603
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2026218766
- Cited by
- 320
- References
- 31
- FWCI
- 18.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.